Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift.

Fabbri A, Cossa M, Sonzogni A, Bidoli P, Canova S, Cortinovis D, Abbate MI, Calabrese F, Nannini N, Lunardi F, Rossi G, La Rosa S, Capella C, Tamborini E, Perrone F, Busico A, Capone I, Valeri B, Pastorino U, Albini A, Pelosi G.

Virchows Arch. 2017 Apr 27. doi: 10.1007/s00428-017-2130-2. [Epub ahead of print]

PMID:
28451756
2.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group..

Lancet Respir Med. 2017 Apr 10. pii: S2213-2600(17)30129-7. doi: 10.1016/S2213-2600(17)30129-7. [Epub ahead of print]

PMID:
28408243
3.

Focus on Nivolumab in NSCLC.

Cortinovis DL, Canova S, Abbate M, Colonese F, Bidoli P.

Front Med (Lausanne). 2016 Dec 13;3:67. doi: 10.3389/fmed.2016.00067. eCollection 2016. Review.

4.

Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients.

Canova S, Cicchiello F, Agustoni F, Bianchini G, Abbate MI, Bidoli P, Cortinovis DL.

Tumori. 2017 Mar 24;103(2):143-147. doi: 10.5301/tj.5000584. Epub 2016 Nov 28.

PMID:
28009425
5.

Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.

Gridelli C, Chella A, Valmadre G, Allegrini G, Brighenti M, Bidoli P, Rossi A, Maione P, Migliorino MR, Ricciardi S, DE Marinis F.

Anticancer Res. 2016 Dec;36(12):6535-6540.

PMID:
27919979
6.

Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P.

Tumori. 2017 Jan 21;103(1):e4-e8. doi: 10.5301/tj.5000543.

PMID:
27647223
7.

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.

Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators..

Ann Oncol. 2016 Nov;27(11):2074-2081. Epub 2016 Aug 29.

PMID:
27573560
8.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Oct 25;115(9):e16. doi: 10.1038/bjc.2016.342. Epub 2016 Oct 11. No abstract available.

9.

Comment on: "Is there a role for vitamin D in human reproduction?"

Colonese F, La Rosa VL, Laganà AS, Vitale SG, Cortinovis D, Bidoli P.

Horm Mol Biol Clin Investig. 2017 Jan 1;29(1):37-38. doi: 10.1515/hmbci-2016-0040. No abstract available.

PMID:
27740917
10.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators..

N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.

PMID:
27718847
11.

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.

Dalgleish AG, Stebbing J, Adamson DJ, Arif SS, Bidoli P, Chang D, Cheeseman S, Diaz-Beveridge R, Fernandez-Martos C, Glynne-Jones R, Granetto C, Massuti B, McAdam K, McDermott R, Martín AJ, Papamichael D, Pazo-Cid R, Vieitez JM, Zaniboni A, Carroll KJ, Wagle S, Gaya A, Mudan SS.

Br J Cancer. 2016 Sep 27;115(7):789-96. doi: 10.1038/bjc.2016.271. Epub 2016 Sep 6.

12.

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F.

Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14.

PMID:
27565910
13.

Targeted therapies and immunotherapy in non-small-cell lung cancer.

Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S.

Ecancermedicalscience. 2016 Jun 23;10:648. doi: 10.3332/ecancer.2016.648. eCollection 2016. Review.

14.

Interpretation of lung cancer study outcomes.

Cortinovis D, Abbate M, Bidoli P, Pelizzoni D, Canova S.

J Thorac Dis. 2015 Nov;7(11):E541-7. doi: 10.3978/j.issn.2072-1439.2015.11.26.

15.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators..

Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8.

16.

Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc(©) ) in patients with chemotherapy-induced peripheral neuropathy.

Binda D, Cavaletti G, Cornblath DR, Merkies IS; CI-PeriNomS study group..

J Peripher Nerv Syst. 2015 Sep;20(3):328-32. doi: 10.1111/jns.12140.

PMID:
26306547
17.

What are the options for non-small-cell lung cancer patients post second-line therapy?

Cortinovis DL, Canova S, Bidoli P.

Future Oncol. 2015;11(17):2379-82. doi: 10.2217/FON.15.159. Epub 2015 Aug 13. Review. No abstract available.

PMID:
26270000
18.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators..

Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.

PMID:
26045340
19.

Isolated cardiac metastasis from squamous cell esophageal cancer.

Abbate MI, Cicchiello F, Canova S, Cortinovis D, Mariani S, Maffini F, Bidoli P.

Tumori. 2015 Jul 24;101(4):e118-21. doi: 10.5301/tj.5000324.

PMID:
26045127
20.

C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool: an observational study.

Jaconi M, Pagni F, Vacirca F, Leni D, Corso R, Cortinovis D, Bidoli P, Bono F, Cuttin MS, Valente MG, Pesci A, Bedini VA, Leone BE.

Medicine (Baltimore). 2015 Mar;94(12):e698. doi: 10.1097/MD.0000000000000698.

Supplemental Content

Loading ...
Support Center